News for Celcuity Inc. (CELC)

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday. The Dow traded up 0.07% to 44,932.70 ...

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Monday. Shares of Alerus Financial Corporation ALRS rose sharply during Monday's...

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 50 points on Monday. Following the market opening Tuesday, the Dow traded down 0...

MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for on

Celcuity (CELC) has recently secured a new U.S. patent for the clinical dosing regimen of its leading drug candidate, gedatolisib, aimed at treating patients wi

Patent protection for gedatolisib extended until 2042, ensuring long-term market exclusivity. Robust patent portfolio with 13 U.S. patents and 290 forei

• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus

MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for onc

Celcuity Inc. (CELC) to present at TD Cowen and Jefferies Investor Conferences. CEO Brian Sullivan to lead discussions on May 28 and June 5, 2025. Li

Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity First Quarter 2025 Financial Results Webcast Conference Call. At this time all lines are in listen-only mode.

Celcuity (CELC), a cutting-edge biotechnology company, has had its stock position reiterated as a "Buy" by Needham, one of the prominent firms in financial anal

Net Loss: $37 million or $0.86 per share for Q1 2025, compared to $21.6 million or $0.6 per share for Q1 2024.Non-GAAP Adjusted Net Loss: $34.7 million or $0.8

May 14, 2025 / 08:30PM GMTOperator Good afternoon, ladies and gentlemen, and welcome to the Celcuity first-quarter 2025 financial results webcast conference cal

The following slide deck was published by Celcuity Inc.

Celcuity Inc. reveals promising updates on cancer trials with major topline results expected in 2025.

Celcuity Inc. (NASDAQ:CELC) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsApoorva Chaloori - ICR HealthcareBrian Sullivan -...

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. ( CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for onc

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday. Shares of Northrop Grumman Corporation NOC shares fell ...

**media[595708]**